Leap Therapeutics is focused on developing innovative targeted and immuno-oncology therapeutics to combat various types of cancer. Their lead candidate, DKN-01, is a humanized monoclonal antibody that specifically targets the Dickkopf-1 (DKK1) protein, which is expressed in certain tumors. This therapy is currently being evaluated in clinical trials for patients with esophagogastric, gynecologic, and colorectal cancers. Additionally, Leap is advancing FL-301, another humanized monoclonal antibody that targets Claudin18.2, aimed at treating gastric and pancreatic cancers. 

In addition to these advanced candidates, Leap Therapeutics is also working on FL-501, a humanized monoclonal antibody that targets the growth and differentiation factor 15 (GDF-15) protein, which is currently in preclinical development. The company emphasizes the importance of understanding tumor expression and identifying new therapeutic targets to develop effective treatments for cancer patients. Through these efforts, Leap Therapeutics aims to provide new therapies and combinations that can significantly improve patient outcomes in oncology.

United States

Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.

For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com.

Cancer

Digestive System Diseases

Leap Therapeutics

Carcinosarcoma

Endometrial cancer

Ovarian cancer

<ul class="font_8">
 <li>DKN-01 is a humanized monoclonal antibody that binds to and specifically blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin and CKAP4/PI3K/AKT signaling pathways, frequently implicated in tumorigenesis.</li>
</ul>

Sirexatamab (DKN-01) +/- Paclitaxel

Sirexatamab (DKN-01) + Pembrolizumab

Gastric cancer

Pancreatic cancer

FL-301 is a fully human monoclonal antibody that binds to and blocks Claudin18.2. In nonclinical models presented at the American Association for Cancer Research (“AACR”) 2020 Annual Meeting, FL-301 was shown to have 10-20x higher affinity to Claudin18.2 than zolbetuximab and specificity to both gastric and pancreatic tumors. Through Fc engineering, FL-301 has been Table of Contents 10 designed with enhanced antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, and antibody dependent cellular phagocytosis, which are three mechanisms that can lead to improved cancer cell killing and greater potency relative to zolbetuximab in nonclinical models.

FL-301

Gastroesophageal junction tumors

DKN-01 is a humanized monoclonal antibody that binds to and specifically blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin and CKAP4/PI3K/AKT signaling pathways, frequently implicated in tumorigenesis.

Leap Therapeutics

Company Details